Lilly’s new data show its oral GLP-1 beating Novo’s on major benchmarks.

Can the neurovascular effects of GLP-1s play a role in treating migraine?

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but ...

Feb 26 () - Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss ‌pill, ...

In a move expected to benefit thousands of New Jersey residents living with obesity and type 2 diabetes, Novo Nordisk, whose ...

Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, ...

Have you noticed the side effects listed for one of those new drugs being advertised on TV? It may seem as if one of those marvelous medicines might be a good solution for your problem, but the long ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

For many young adults in India, the fastest route to shedding kilograms isn’t the gym—it’s a pill. Once prescribed for type 2 diabetes, drugs such as Rybelsus, ...

The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a ...